nodes	percent_of_prediction	percent_of_DWPC	metapath
Brompheniramine—CYP2E1—Parkinson's disease	0.465	0.577	CbGaD
Brompheniramine—CYP2D6—Parkinson's disease	0.341	0.423	CbGaD
Brompheniramine—Captodiame—DRD3—Parkinson's disease	0.00138	0.234	CrCbGaD
Brompheniramine—CHRM4—head—Parkinson's disease	0.00074	0.0338	CbGeAlD
Brompheniramine—CHRM4—nervous system—Parkinson's disease	0.000702	0.032	CbGeAlD
Brompheniramine—CHRM2—forebrain—Parkinson's disease	0.000693	0.0316	CbGeAlD
Brompheniramine—CHRM4—central nervous system—Parkinson's disease	0.000675	0.0308	CbGeAlD
Brompheniramine—CHRM1—forebrain—Parkinson's disease	0.000631	0.0288	CbGeAlD
Brompheniramine—CHRM2—cardiovascular system—Parkinson's disease	0.000586	0.0267	CbGeAlD
Brompheniramine—CHRM5—head—Parkinson's disease	0.000578	0.0264	CbGeAlD
Brompheniramine—Chlorphenamine—SLC6A3—Parkinson's disease	0.000577	0.0983	CrCbGaD
Brompheniramine—CHRM3—forebrain—Parkinson's disease	0.000565	0.0258	CbGeAlD
Brompheniramine—Mepyramine—CYP2D6—Parkinson's disease	0.000564	0.096	CrCbGaD
Brompheniramine—CYP2D6—hindbrain—Parkinson's disease	0.000552	0.0252	CbGeAlD
Brompheniramine—CHRM5—nervous system—Parkinson's disease	0.000548	0.025	CbGeAlD
Brompheniramine—CHRM4—brain—Parkinson's disease	0.000536	0.0245	CbGeAlD
Brompheniramine—CHRM1—cardiovascular system—Parkinson's disease	0.000534	0.0243	CbGeAlD
Brompheniramine—CHRM5—central nervous system—Parkinson's disease	0.000528	0.0241	CbGeAlD
Brompheniramine—Tripelennamine—CYP2D6—Parkinson's disease	0.000522	0.0888	CrCbGaD
Brompheniramine—KCNH2—forebrain—Parkinson's disease	0.000501	0.0228	CbGeAlD
Brompheniramine—Carbinoxamine—CYP2E1—Parkinson's disease	0.000486	0.0827	CrCbGaD
Brompheniramine—KCNH2—cardiovascular system—Parkinson's disease	0.000424	0.0193	CbGeAlD
Brompheniramine—CHRM5—brain—Parkinson's disease	0.000419	0.0191	CbGeAlD
Brompheniramine—Tolterodine—CYP2D6—Parkinson's disease	0.000416	0.0708	CrCbGaD
Brompheniramine—HRH1—forebrain—Parkinson's disease	0.000401	0.0183	CbGeAlD
Brompheniramine—CHRM2—head—Parkinson's disease	0.000397	0.0181	CbGeAlD
Brompheniramine—CHRM2—nervous system—Parkinson's disease	0.000376	0.0172	CbGeAlD
Brompheniramine—CHRM2—central nervous system—Parkinson's disease	0.000362	0.0165	CbGeAlD
Brompheniramine—KCNH2—medulla oblongata—Parkinson's disease	0.000362	0.0165	CbGeAlD
Brompheniramine—CHRM1—head—Parkinson's disease	0.000361	0.0165	CbGeAlD
Brompheniramine—Carbinoxamine—CYP2D6—Parkinson's disease	0.000357	0.0607	CrCbGaD
Brompheniramine—Promazine—DRD1—Parkinson's disease	0.000356	0.0607	CrCbGaD
Brompheniramine—CYP2B6—cardiovascular system—Parkinson's disease	0.000348	0.0159	CbGeAlD
Brompheniramine—CYP2C9—cardiovascular system—Parkinson's disease	0.000344	0.0157	CbGeAlD
Brompheniramine—CHRM1—nervous system—Parkinson's disease	0.000343	0.0156	CbGeAlD
Brompheniramine—KCNH2—midbrain—Parkinson's disease	0.000331	0.0151	CbGeAlD
Brompheniramine—CHRM1—central nervous system—Parkinson's disease	0.00033	0.015	CbGeAlD
Brompheniramine—CYP2E1—cardiovascular system—Parkinson's disease	0.000326	0.0149	CbGeAlD
Brompheniramine—CHRM3—head—Parkinson's disease	0.000323	0.0148	CbGeAlD
Brompheniramine—KCNH2—spinal cord—Parkinson's disease	0.000323	0.0147	CbGeAlD
Brompheniramine—CYP2D6—brainstem—Parkinson's disease	0.000316	0.0144	CbGeAlD
Brompheniramine—CHRM3—nervous system—Parkinson's disease	0.000307	0.014	CbGeAlD
Brompheniramine—CYP2D6—forebrain—Parkinson's disease	0.000305	0.0139	CbGeAlD
Brompheniramine—Chlorphenamine—CYP2D6—Parkinson's disease	0.000303	0.0516	CrCbGaD
Brompheniramine—CHRM3—central nervous system—Parkinson's disease	0.000295	0.0135	CbGeAlD
Brompheniramine—CHRM2—brain—Parkinson's disease	0.000288	0.0131	CbGeAlD
Brompheniramine—KCNH2—head—Parkinson's disease	0.000287	0.0131	CbGeAlD
Brompheniramine—CYP2E1—medulla oblongata—Parkinson's disease	0.000279	0.0127	CbGeAlD
Brompheniramine—KCNH2—nervous system—Parkinson's disease	0.000272	0.0124	CbGeAlD
Brompheniramine—Orphenadrine—CYP2E1—Parkinson's disease	0.000265	0.0451	CrCbGaD
Brompheniramine—CHRM1—brain—Parkinson's disease	0.000262	0.0119	CbGeAlD
Brompheniramine—KCNH2—central nervous system—Parkinson's disease	0.000262	0.0119	CbGeAlD
Brompheniramine—KCNH2—cerebellum—Parkinson's disease	0.000256	0.0117	CbGeAlD
Brompheniramine—Promazine—DRD2—Parkinson's disease	0.000251	0.0428	CrCbGaD
Brompheniramine—CYP2E1—spinal cord—Parkinson's disease	0.000249	0.0113	CbGeAlD
Brompheniramine—CYP2B6—head—Parkinson's disease	0.000235	0.0107	CbGeAlD
Brompheniramine—CHRM3—brain—Parkinson's disease	0.000234	0.0107	CbGeAlD
Brompheniramine—HRH1—head—Parkinson's disease	0.00023	0.0105	CbGeAlD
Brompheniramine—CYP2B6—nervous system—Parkinson's disease	0.000223	0.0102	CbGeAlD
Brompheniramine—CYP2E1—head—Parkinson's disease	0.000221	0.0101	CbGeAlD
Brompheniramine—HRH1—nervous system—Parkinson's disease	0.000218	0.00994	CbGeAlD
Brompheniramine—CYP2B6—central nervous system—Parkinson's disease	0.000215	0.0098	CbGeAlD
Brompheniramine—HRH1—central nervous system—Parkinson's disease	0.00021	0.00957	CbGeAlD
Brompheniramine—CYP2E1—nervous system—Parkinson's disease	0.000209	0.00955	CbGeAlD
Brompheniramine—KCNH2—brain—Parkinson's disease	0.000208	0.00948	CbGeAlD
Brompheniramine—Diphenhydramine—CYP2D6—Parkinson's disease	0.000206	0.035	CrCbGaD
Brompheniramine—CYP2E1—central nervous system—Parkinson's disease	0.000202	0.0092	CbGeAlD
Brompheniramine—CYP2E1—cerebellum—Parkinson's disease	0.000197	0.00899	CbGeAlD
Brompheniramine—Promazine—HTR2A—Parkinson's disease	0.000194	0.0331	CrCbGaD
Brompheniramine—CYP2C8—brain—Parkinson's disease	0.00019	0.00867	CbGeAlD
Brompheniramine—CYP2D6—head—Parkinson's disease	0.000175	0.00798	CbGeAlD
Brompheniramine—CYP2B6—brain—Parkinson's disease	0.000171	0.00778	CbGeAlD
Brompheniramine—CYP3A4—nervous system—Parkinson's disease	0.000168	0.00768	CbGeAlD
Brompheniramine—HRH1—brain—Parkinson's disease	0.000167	0.0076	CbGeAlD
Brompheniramine—CYP2D6—nervous system—Parkinson's disease	0.000166	0.00756	CbGeAlD
Brompheniramine—CYP3A4—central nervous system—Parkinson's disease	0.000162	0.0074	CbGeAlD
Brompheniramine—CYP2E1—brain—Parkinson's disease	0.00016	0.0073	CbGeAlD
Brompheniramine—CYP2D6—central nervous system—Parkinson's disease	0.00016	0.00728	CbGeAlD
Brompheniramine—CYP2D6—cerebellum—Parkinson's disease	0.000156	0.00712	CbGeAlD
Brompheniramine—CYP2D6—brain—Parkinson's disease	0.000127	0.00578	CbGeAlD
Brompheniramine—CHRM2—GPCR downstream signaling—HTR2A—Parkinson's disease	2.22e-05	0.000134	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	2.19e-05	0.000132	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—INSR—Parkinson's disease	2.18e-05	0.000131	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—INSR—Parkinson's disease	2.17e-05	0.000131	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—INSR—Parkinson's disease	2.16e-05	0.00013	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—CYP2E1—Parkinson's disease	2.15e-05	0.00013	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—IGF2—Parkinson's disease	2.14e-05	0.000129	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—INSR—Parkinson's disease	2.14e-05	0.000129	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—NQO1—Parkinson's disease	2.12e-05	0.000128	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—GSTA4—Parkinson's disease	2.12e-05	0.000128	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—GSTA4—Parkinson's disease	2.1e-05	0.000127	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—TH—Parkinson's disease	2.09e-05	0.000126	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—PLA2G6—Parkinson's disease	2.07e-05	0.000125	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—Parkinson's disease	2.07e-05	0.000125	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—IGF1R—Parkinson's disease	2.07e-05	0.000125	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—FGB—Parkinson's disease	2.06e-05	0.000124	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—MAOB—Parkinson's disease	2.05e-05	0.000124	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—IGF2—Parkinson's disease	2.05e-05	0.000124	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—HTR2A—Parkinson's disease	2.05e-05	0.000124	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—FGB—Parkinson's disease	2.05e-05	0.000124	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—EDN1—Parkinson's disease	2.05e-05	0.000124	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—HTR1A—Parkinson's disease	2.05e-05	0.000123	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—HTR2A—Parkinson's disease	2.04e-05	0.000123	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—FGB—Parkinson's disease	2.04e-05	0.000123	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—HTR1A—Parkinson's disease	2.04e-05	0.000123	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—HTR2A—Parkinson's disease	2.04e-05	0.000123	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—HTR1A—Parkinson's disease	2.03e-05	0.000123	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—FGB—Parkinson's disease	2.02e-05	0.000122	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—CYP2D6—Parkinson's disease	2.02e-05	0.000122	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—HTR2A—Parkinson's disease	2.02e-05	0.000122	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—TAC1—Parkinson's disease	2.01e-05	0.000122	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—HTR1A—Parkinson's disease	2.01e-05	0.000121	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—CYCS—Parkinson's disease	2.01e-05	0.000121	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—TAC1—Parkinson's disease	2.01e-05	0.000121	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—TAC1—Parkinson's disease	2e-05	0.000121	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—DBH—Parkinson's disease	2e-05	0.000121	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—FBP1—Parkinson's disease	2e-05	0.000121	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—GBA—Parkinson's disease	2e-05	0.000121	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—IGF1R—Parkinson's disease	1.98e-05	0.00012	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—CTGF—Parkinson's disease	1.98e-05	0.00012	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—TAC1—Parkinson's disease	1.98e-05	0.00012	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—CYP2D6—Parkinson's disease	1.98e-05	0.000119	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—DRD1—Parkinson's disease	1.98e-05	0.000119	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—DRD1—Parkinson's disease	1.97e-05	0.000119	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—DRD1—Parkinson's disease	1.96e-05	0.000118	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—EDN1—Parkinson's disease	1.96e-05	0.000118	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	1.95e-05	0.000118	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—DRD1—Parkinson's disease	1.94e-05	0.000117	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—CTGF—Parkinson's disease	1.94e-05	0.000117	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—DRD3—Parkinson's disease	1.91e-05	0.000115	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—PLA2G6—Parkinson's disease	1.91e-05	0.000115	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—DRD3—Parkinson's disease	1.91e-05	0.000115	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—DRD3—Parkinson's disease	1.9e-05	0.000115	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—PLA2G6—Parkinson's disease	1.89e-05	0.000114	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—MAOB—Parkinson's disease	1.89e-05	0.000114	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—DRD3—Parkinson's disease	1.88e-05	0.000114	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—NGF—Parkinson's disease	1.88e-05	0.000114	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—MAOB—Parkinson's disease	1.87e-05	0.000113	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—CYP2E1—Parkinson's disease	1.85e-05	0.000111	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—NQO1—Parkinson's disease	1.83e-05	0.00011	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—NGF—Parkinson's disease	1.8e-05	0.000109	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—TH—Parkinson's disease	1.8e-05	0.000109	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—HTR2A—Parkinson's disease	1.79e-05	0.000108	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—NQO1—Parkinson's disease	1.79e-05	0.000108	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—ADRBK1—Parkinson's disease	1.79e-05	0.000108	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	1.78e-05	0.000107	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—ADRBK1—Parkinson's disease	1.78e-05	0.000107	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—COMT—Parkinson's disease	1.78e-05	0.000107	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—ADRBK1—Parkinson's disease	1.77e-05	0.000107	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—GSTP1—Parkinson's disease	1.77e-05	0.000107	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—MAOA—Parkinson's disease	1.77e-05	0.000107	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—TH—Parkinson's disease	1.76e-05	0.000106	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—ADRBK1—Parkinson's disease	1.76e-05	0.000106	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—HMOX1—Parkinson's disease	1.75e-05	0.000105	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—HTR7—Parkinson's disease	1.73e-05	0.000104	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—DRD2—Parkinson's disease	1.73e-05	0.000104	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—CYCS—Parkinson's disease	1.73e-05	0.000104	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—HTR7—Parkinson's disease	1.72e-05	0.000104	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—DRD2—Parkinson's disease	1.72e-05	0.000104	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—DRD2—Parkinson's disease	1.72e-05	0.000104	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—HTR7—Parkinson's disease	1.72e-05	0.000104	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—HTR2A—Parkinson's disease	1.72e-05	0.000103	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—CYP2D6—Parkinson's disease	1.71e-05	0.000103	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—DRD2—Parkinson's disease	1.7e-05	0.000103	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—HTR7—Parkinson's disease	1.7e-05	0.000103	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—CYCS—Parkinson's disease	1.69e-05	0.000102	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—CTGF—Parkinson's disease	1.68e-05	0.000101	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—ABCB1—Parkinson's disease	1.68e-05	0.000101	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—APOE—Parkinson's disease	1.67e-05	0.0001	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—GSTM1—Parkinson's disease	1.63e-05	9.81e-05	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—APOE—Parkinson's disease	1.59e-05	9.62e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—CYP2E1—Parkinson's disease	1.56e-05	9.43e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—GPX1—Parkinson's disease	1.56e-05	9.4e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—NQO1—Parkinson's disease	1.55e-05	9.33e-05	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—COMT—Parkinson's disease	1.53e-05	9.23e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—CYP2D6—Parkinson's disease	1.53e-05	9.21e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—TH—Parkinson's disease	1.52e-05	9.19e-05	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—GSTP1—Parkinson's disease	1.52e-05	9.19e-05	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—MAOA—Parkinson's disease	1.52e-05	9.17e-05	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—HMOX1—Parkinson's disease	1.5e-05	9.06e-05	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—COMT—Parkinson's disease	1.5e-05	9.04e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—CTGF—Parkinson's disease	1.5e-05	9.04e-05	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—GSTP1—Parkinson's disease	1.49e-05	9e-05	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—MAOA—Parkinson's disease	1.49e-05	8.98e-05	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—HMOX1—Parkinson's disease	1.47e-05	8.88e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—DDC—Parkinson's disease	1.47e-05	8.85e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—CYCS—Parkinson's disease	1.46e-05	8.83e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—IGF2—Parkinson's disease	1.45e-05	8.75e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—IGF2—Parkinson's disease	1.45e-05	8.72e-05	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—ABCB1—Parkinson's disease	1.44e-05	8.7e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—IGF2—Parkinson's disease	1.44e-05	8.69e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—MTHFR—Parkinson's disease	1.44e-05	8.67e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—IGF2—Parkinson's disease	1.43e-05	8.61e-05	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—INS—Parkinson's disease	1.42e-05	8.58e-05	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—ABCB1—Parkinson's disease	1.41e-05	8.52e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—IGF1R—Parkinson's disease	1.4e-05	8.46e-05	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—GSTM1—Parkinson's disease	1.4e-05	8.44e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—IGF1R—Parkinson's disease	1.4e-05	8.43e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—CYP2E1—Parkinson's disease	1.4e-05	8.42e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—IGF1R—Parkinson's disease	1.39e-05	8.4e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—CYP2D6—Parkinson's disease	1.39e-05	8.39e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—GSTA4—Parkinson's disease	1.39e-05	8.36e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—EDN1—Parkinson's disease	1.39e-05	8.36e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—EDN1—Parkinson's disease	1.38e-05	8.33e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—NQO1—Parkinson's disease	1.38e-05	8.32e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—IGF1R—Parkinson's disease	1.38e-05	8.32e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—CTGF—Parkinson's disease	1.38e-05	8.31e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—EDN1—Parkinson's disease	1.38e-05	8.3e-05	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—GSTM1—Parkinson's disease	1.37e-05	8.27e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—CTGF—Parkinson's disease	1.37e-05	8.24e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—EDN1—Parkinson's disease	1.36e-05	8.22e-05	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—INS—Parkinson's disease	1.36e-05	8.22e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—TH—Parkinson's disease	1.36e-05	8.2e-05	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—GPX1—Parkinson's disease	1.34e-05	8.09e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—APOE—Parkinson's disease	1.34e-05	8.08e-05	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—GPX1—Parkinson's disease	1.31e-05	7.92e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—CYCS—Parkinson's disease	1.31e-05	7.88e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—COMT—Parkinson's disease	1.3e-05	7.82e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—GSTP1—Parkinson's disease	1.29e-05	7.78e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—MAOA—Parkinson's disease	1.29e-05	7.76e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—CYP2E1—Parkinson's disease	1.28e-05	7.74e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—NGF—Parkinson's disease	1.27e-05	7.68e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—CYP2E1—Parkinson's disease	1.27e-05	7.68e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—HMOX1—Parkinson's disease	1.27e-05	7.67e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—NQO1—Parkinson's disease	1.27e-05	7.66e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—NGF—Parkinson's disease	1.27e-05	7.65e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—NGF—Parkinson's disease	1.26e-05	7.63e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—NQO1—Parkinson's disease	1.26e-05	7.59e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—NGF—Parkinson's disease	1.25e-05	7.56e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—TH—Parkinson's disease	1.25e-05	7.55e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—PLA2G6—Parkinson's disease	1.25e-05	7.52e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—TH—Parkinson's disease	1.24e-05	7.48e-05	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—MTHFR—Parkinson's disease	1.24e-05	7.46e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—MAOB—Parkinson's disease	1.23e-05	7.45e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—ABCB1—Parkinson's disease	1.22e-05	7.36e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—HTR2A—Parkinson's disease	1.21e-05	7.31e-05	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—MTHFR—Parkinson's disease	1.21e-05	7.31e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—HTR2A—Parkinson's disease	1.21e-05	7.29e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—HTR2A—Parkinson's disease	1.2e-05	7.26e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—CYCS—Parkinson's disease	1.2e-05	7.25e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—HTR2A—Parkinson's disease	1.19e-05	7.19e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—CYCS—Parkinson's disease	1.19e-05	7.18e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—GSTM1—Parkinson's disease	1.18e-05	7.15e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—COMT—Parkinson's disease	1.16e-05	6.98e-05	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—APOE—Parkinson's disease	1.15e-05	6.95e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—GSTP1—Parkinson's disease	1.15e-05	6.94e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—MAOA—Parkinson's disease	1.15e-05	6.93e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—INS—Parkinson's disease	1.14e-05	6.9e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—HMOX1—Parkinson's disease	1.14e-05	6.85e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—GPX1—Parkinson's disease	1.13e-05	6.85e-05	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—APOE—Parkinson's disease	1.13e-05	6.8e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—APOE—Parkinson's disease	1.13e-05	6.8e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—APOE—Parkinson's disease	1.12e-05	6.77e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—APOE—Parkinson's disease	1.12e-05	6.75e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—APOE—Parkinson's disease	1.11e-05	6.69e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—ABCB1—Parkinson's disease	1.09e-05	6.57e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—COMT—Parkinson's disease	1.06e-05	6.42e-05	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—CASP3—Parkinson's disease	1.06e-05	6.39e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—GSTP1—Parkinson's disease	1.06e-05	6.39e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—GSTM1—Parkinson's disease	1.06e-05	6.38e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—MAOA—Parkinson's disease	1.06e-05	6.37e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—COMT—Parkinson's disease	1.05e-05	6.36e-05	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling by GPCR—IL6—Parkinson's disease	1.05e-05	6.35e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—GSTP1—Parkinson's disease	1.05e-05	6.33e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—MTHFR—Parkinson's disease	1.05e-05	6.32e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—MAOA—Parkinson's disease	1.05e-05	6.32e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—HMOX1—Parkinson's disease	1.04e-05	6.3e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—HMOX1—Parkinson's disease	1.03e-05	6.24e-05	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—CASP3—Parkinson's disease	1.01e-05	6.12e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—GPX1—Parkinson's disease	1.01e-05	6.11e-05	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling by GPCR—IL6—Parkinson's disease	1.01e-05	6.08e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—ABCB1—Parkinson's disease	1e-05	6.05e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—ABCB1—Parkinson's disease	9.93e-06	5.99e-05	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—INS—Parkinson's disease	9.84e-06	5.93e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—APOE—Parkinson's disease	9.75e-06	5.88e-05	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—MAPK8—Parkinson's disease	9.73e-06	5.87e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—GSTM1—Parkinson's disease	9.73e-06	5.87e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—GSTM1—Parkinson's disease	9.64e-06	5.82e-05	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—INS—Parkinson's disease	9.64e-06	5.81e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—INS—Parkinson's disease	9.62e-06	5.81e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—INS—Parkinson's disease	9.59e-06	5.79e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—INS—Parkinson's disease	9.56e-06	5.77e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—INS—Parkinson's disease	9.47e-06	5.71e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—MTHFR—Parkinson's disease	9.35e-06	5.64e-05	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—MAPK8—Parkinson's disease	9.32e-06	5.62e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—GPX1—Parkinson's disease	9.32e-06	5.62e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—GPX1—Parkinson's disease	9.24e-06	5.57e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—CYP2D6—Parkinson's disease	9.18e-06	5.54e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—CTGF—Parkinson's disease	9.01e-06	5.43e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—APOE—Parkinson's disease	8.7e-06	5.25e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—MTHFR—Parkinson's disease	8.6e-06	5.19e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—MTHFR—Parkinson's disease	8.52e-06	5.14e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—CYP2E1—Parkinson's disease	8.39e-06	5.06e-05	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—INS—Parkinson's disease	8.33e-06	5.02e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—NQO1—Parkinson's disease	8.3e-06	5.01e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—TH—Parkinson's disease	8.18e-06	4.93e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—APOE—Parkinson's disease	8e-06	4.83e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—APOE—Parkinson's disease	7.93e-06	4.79e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—CYCS—Parkinson's disease	7.85e-06	4.74e-05	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—INS—Parkinson's disease	7.43e-06	4.48e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—CASP3—Parkinson's disease	7.16e-06	4.32e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—CASP3—Parkinson's disease	7.14e-06	4.31e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—CASP3—Parkinson's disease	7.12e-06	4.29e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—IL6—Parkinson's disease	7.12e-06	4.29e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—IL6—Parkinson's disease	7.1e-06	4.28e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—IL6—Parkinson's disease	7.07e-06	4.27e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—CASP3—Parkinson's disease	7.05e-06	4.25e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—IL6—Parkinson's disease	7e-06	4.23e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—COMT—Parkinson's disease	6.95e-06	4.2e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—GSTP1—Parkinson's disease	6.92e-06	4.18e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—MAOA—Parkinson's disease	6.9e-06	4.17e-05	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—INS—Parkinson's disease	6.84e-06	4.12e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—HMOX1—Parkinson's disease	6.83e-06	4.12e-05	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—INS—Parkinson's disease	6.78e-06	4.09e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—MAPK8—Parkinson's disease	6.58e-06	3.97e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—MAPK8—Parkinson's disease	6.56e-06	3.96e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—ABCB1—Parkinson's disease	6.55e-06	3.95e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—MAPK8—Parkinson's disease	6.54e-06	3.95e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—MAPK8—Parkinson's disease	6.48e-06	3.91e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—GSTM1—Parkinson's disease	6.36e-06	3.84e-05	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—IL6—Parkinson's disease	6.22e-06	3.75e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—GPX1—Parkinson's disease	6.09e-06	3.67e-05	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—IL6—Parkinson's disease	5.95e-06	3.59e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—MTHFR—Parkinson's disease	5.62e-06	3.39e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—APOE—Parkinson's disease	5.23e-06	3.16e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—INS—Parkinson's disease	4.47e-06	2.7e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—IL6—Parkinson's disease	4.2e-06	2.54e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—IL6—Parkinson's disease	4.19e-06	2.53e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—IL6—Parkinson's disease	4.18e-06	2.52e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—IL6—Parkinson's disease	4.14e-06	2.5e-05	CbGpPWpGaD
